[{"id":"f8d87fba-1ad4-4662-baab-e93772837874","acronym":"Agni-01","url":"https://clinicaltrials.gov/study/NCT06060613","created_at":"2023-09-29T19:11:12.291Z","updated_at":"2025-02-25T14:03:51.690Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","source_id_and_acronym":"NCT06060613 - Agni-01","lead_sponsor":"Obsidian Therapeutics, Inc.","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • OBX-115"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2025-02-19"},{"id":"46f30880-78f6-435b-bfdc-3b82d7b254cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06581419","created_at":"2025-02-25T20:15:26.057Z","updated_at":"2025-02-25T20:15:26.057Z","phase":"Phase 1/2","brief_title":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","source_id_and_acronym":"NCT06581419","lead_sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IAP0971"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 12/31/2024","start_date":" 12/31/2024","primary_txt":" Primary completion: 08/01/2029","primary_completion_date":" 08/01/2029","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-15"},{"id":"b6b2754e-5306-4023-a3e5-75d3f7fe5848","acronym":"","url":"https://clinicaltrials.gov/study/NCT05620134","created_at":"2022-11-17T14:57:00.380Z","updated_at":"2024-07-02T16:35:08.649Z","phase":"Phase 1/2","brief_title":"Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer","source_id_and_acronym":"NCT05620134","lead_sponsor":"Salubris Biotherapeutics Inc","biomarkers":" HER-2 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["HER-2 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SAL008"],"overall_status":"Recruiting","enrollment":" Enrollment 263","initiation":"Initiation: 10/17/2022","start_date":" 10/17/2022","primary_txt":" Primary completion: 10/17/2025","primary_completion_date":" 10/17/2025","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2024-04-19"},{"id":"522ce461-bd5b-48fe-83ce-bfdef14e9b4b","acronym":"GEN001-201","url":"https://clinicaltrials.gov/study/NCT05419362","created_at":"2022-06-15T16:54:51.189Z","updated_at":"2025-02-25T16:17:49.248Z","phase":"Phase 2","brief_title":"GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer","source_id_and_acronym":"NCT05419362 - GEN001-201","lead_sponsor":"Genome \u0026 Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • GEN-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-17"},{"id":"ac8040d4-cfc1-4fe3-9ea2-d1cab77d649a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05396391","created_at":"2022-05-31T12:54:38.615Z","updated_at":"2024-07-02T16:35:42.451Z","phase":"Phase 1/2","brief_title":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","source_id_and_acronym":"NCT05396391","lead_sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IAP0971"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 06/22/2022","start_date":" 06/22/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2023-07-20"},{"id":"06cedc2c-5fd9-4935-a1db-659225305def","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079503","created_at":"2021-10-15T14:53:04.668Z","updated_at":"2024-07-02T16:36:22.855Z","phase":"","brief_title":"Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT05079503","lead_sponsor":"Korean Cancer Study Group","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GEN-001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 01/30/2024","study_completion_date":" 01/30/2024","last_update_posted":"2021-10-15"}]